Home›Research›Compare›AICAR vs Semaglutide
Peptide ComparisonAICAR vs Semaglutide
Both are Metabolic peptides.
Semaglutide
GLP-1
Half-life: ~7 days (once-weekly dosing)
813 providers listed
Semaglutide is FDA-approved, while AICAR is investigational — the clearest structural difference between them.
AICAR
Half-life
—
Semaglutide
Half-life
~7 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Semaglutide |
| Further along in FDA review | Semaglutide |
| Oral administration option | Semaglutide |
| Lower typical price per mg | AICAR |
| More provider options (5 vs 813) | Semaglutide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
AICAR
Semaglutide
AICAR
MiR-27b-3p suppresses proliferation and testosterone synthesis in goat Leydig cells by activating the AMPK pa…
The AMPK-PGC-1α-SIRT3 axis mediates mitochondrial metabolic dysfunction and neuronal senescence induced by Al…
Berberine Regulates Hepatic Fatty Acid Metabolism via AMPK/SIRT1/PGC-1α Pathway.
Pharmacological inhibition of TRPM4 channel stabilizes atherosclerotic plaque via inhibiting AMPK-Beclin1-med…
+2 more
Semaglutide
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.
+1 more
About AICAR
Converted intracellularly to ZMP, a potent AMPK activator. AMPK activation increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis — the same metabolic pathways activated by sustained aerobic exercise.
About Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
AICAR
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Semaglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
AICAR
Semaglutide
Where to source these peptides
AICAR
5 listed
Browse directory →
Providers offeringSemaglutide
813 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated September 28, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). AICAR vs Semaglutide — Per-mg Price Comparison. Retrieved October 1, 2026, from https://peptidebase.io/peptides/compare/aicar/semaglutide